Which has grown faster, HALO or TEM?

Over the past five years, TEM grew revenue faster — HALO at a 32.18% CAGR versus TEM at 38.24%.

Is HALO or TEM more profitable?

HALO runs the higher net margin — HALO at 24.86% versus TEM at -17.77%.

Halozyme Therapeutics, Inc. (HALO) vs Tempus AI, Inc. (TEM)

A side-by-side comparison of Halozyme Therapeutics, Inc. and Tempus AI, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

HALO

Halozyme Therapeutics, Inc.

$12.83B

$108.15HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT

TEM

Tempus AI, Inc.

$13.36B

$76.27HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT

Total return — HALO vs TEM

growth of $100 · dividends reinvested · last 2y

HALO +117.0% (+47.3%/yr)TEM +107.6% (+44.1%/yr)HALO compounded faster over this window

HALO TEM

HALO vs TEM: by the numbers

•TEM is the larger company ($13.36B vs $12.83B market cap).
•HALO is profitable (24.86% net margin) while TEM runs a net loss (-17.77%).
•TEM grew revenue faster over the past five years (38.24% vs 32.18% CAGR).

Metrics side by side

Valuation

Metric	HALO	TEM
P/E ratio	32.28	N/A
Forward P/E	12.85	N/A
PEG ratio	1.40	N/A
P/S ratio	7.71	9.33
P/B ratio	89.37	30.03
EV / EBITDA	14.04	N/A
FCF yield	6.28%	N/A

Profitability

Metric	HALO	TEM
Gross margin	78.18%	63.98%
Operating margin	56.77%	-19.76%
Net margin	24.86%	-17.77%
ROE	288.13%	-57.18%
ROIC	27.42%	-14.34%

Growth (annualized)

Metric	HALO	TEM
Revenue CAGR (5Y)	32.18%	38.24%
EPS CAGR (5Y)	22.68%	N/A
FCF CAGR (5Y)	40.08%	N/A
Total return CAGR (5Y)	22.18%	N/A

Frequently asked

Which has grown faster, HALO or TEM?: Over the past five years, TEM grew revenue faster — HALO at a 32.18% CAGR versus TEM at 38.24%.
Is HALO or TEM more profitable?: HALO runs the higher net margin — HALO at 24.86% versus TEM at -17.77%.

Go deeper

Full HALO analysis Full TEM analysis Interactive comparison tool

Dig into the metrics

Halozyme Therapeutics P/E ratio Halozyme Therapeutics ROE Tempus AI ROE Halozyme Therapeutics operating margin Tempus AI operating margin Halozyme Therapeutics revenue growth Tempus AI revenue growth Halozyme Therapeutics free cash flow Tempus AI free cash flow

Halozyme Therapeutics & Tempus AI appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.